Effect of nitroxoline on angiogenesis and growth of human bladder cancer

Journal of the National Cancer Institute

Volumn 102, Issue 24, 2010, Pages 1855-1873

  Shim, Joong Sup ^a   Matsui, Yoshiyuki ^d   Bhat, Shridhar ^a   Nacev, Benjamin A ^a,b   Xu, Jing ^a   Bhang, Hyo Eun C ^a   Dhara, Surajit ^c   Han, Kee Chung ^a   Chong, Curtis R ^a,b   Pomper, Martin G ^a,c   So, Alan ^d   Liu, Jun O ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Medical Scientist Training Program   (United States)

^c Department of Radiology ^*  (Australia)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG VEHICLE; MATRIGEL; METHIONYL AMINOPEPTIDASE 2; NITROXOLINE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; BLADDER CANCER; CANCER GROWTH; CELL PROLIFERATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HIGH THROUGHPUT SCREENING; IC 50; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENESCENCE; TUMOR XENOGRAFT; UMBILICAL VEIN;

ACETYLATION; AMINOPEPTIDASES; ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-INFECTIVE AGENTS, URINARY; BREAST NEOPLASMS; CELL PROLIFERATION; COLLAGEN; CYCLOHEXANES; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; DRUG SYNERGISM; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LAMININ; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NITROQUINOLINES; PROTEOGLYCANS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SESQUITERPENES; SIRTUIN 1; TRANSFECTION; UMBILICAL VEINS; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78650350269     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq457     Document Type: Article

References (58)

1. Colville-Nash PR, Scott DL. Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis. 1992;51(7): 919-925.
2. Ashton N. Retinal angiogenesis in the human embryo. Br Med Bull. 1970;26(2):103-106.
3. Folkman J, Merler E, Abernathy C, et al. Isolation of a tumor factor responsible for angiogenesis. J Exp Med. 1971;133(2):275-288.
4. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol. 2001;61(3):253-270.
5. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182-1186.
6. Folkman J, Langer R, Linhardt RJ, et al. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science. 1983;221(4612):719-725.
7. Ma J, Waxman DJ. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther. 2008;7(12): 3670-3684.
8. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature. 1990;348(6301):555-557.
9. Kruger EA, Figg WD. TNP-470: an angiogenesis inhibitor in clinical development for cancer. Expert Opin Investig Drugs. 2000;9(6): 1383-1396.
10. Bhargava P, Marshall JL, Rizvi N, et al. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res. 1999;5(8):1989-1995.
11. Kudelka AP, Levy T, Verschraegen CF, et al. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res. 1997;3(9):1501-1505.
12. Twardowski P, Gradishar WJ. Clinical trials of antiangiogenic agents. Curr Opin Oncol. 1997;9(6):584-589.
13. Griffth EC, Su Z, Turk BE, et al. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem Biol. 1997;4:461-471.
14. Sin N, Meng L, Wang MQW, et al. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA. 1997;94:6099-6103.
15. a-acetyl transferase families. Trends Biochem Sci. 1998;23:263-267.
16. Yeh JR, Mohan R, Crews CM. The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest. Proc Natl Acad Sci USA. 2000;97(23):12782-12787.
17. Zhang Y, Griffth EC, Sage J, et al. Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc Natl Acad Sci USA. 2000;97(12):6427-6432.
18. Marino JP Jr., Fisher PW, Hofmann GA, et al. Highly potent inhibitors of methionine aminopeptidase-2 based on a 1,2,4-triazole pharmacophore. J Med Chem. 2007;50(16):3777-3785.
19. Sheppard GS, Wang J, Kawai M, et al. Discovery and optimization of anthranilic acid sulfonamides as inhibitors of methionine aminopepti-dase-2: a structural basis for the reduction of albumin binding. J Med Chem. 2006;49(13):3832-3849.
20. Guarente L. Diverse and dynamic functions of the Sir silencing complex. Nat Genet. 1999;23(3):281-285.
21. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature. 2009;460(7255):587-591.
22. Michishita E, Park JY, Burneskis JM, et al. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell. 2005;16(10):4623-4635.
23. Vaziri H, Dessain SK, Ng Eaton E, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001;107(2):149-159.
24. Brooks CL, Gu W. How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer. 2009;9(2):123-128.
25. Liu T, Liu PY, Marshall GM. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res. 2009;69(5):1702-1705.
26. Ota H, Akishita M, Eto M, et al. Sirt1 modulates premature senescencelike phenotype in human endothelial cells. J Mol Cell Cardiol. 2007; 43(5):571-579.
27. Frank RG. New estimates of drug development costs. J Health Econ. 2003;22(2):325-330.
28. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673-683.
29. Chong CR, Chen X, Shi L, et al. A clinical drug library screen identifes astemizole as an antimalarial agent. Nat Chem Biol. 2006;2(8):415-6.
30. Zhang H, Qian DZ, Tan YS, et al. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci USA. 2008;105(50):19579-19586.
31. Chen X, Chong CR, Shi L, et al. Inhibitors of Plasmodium falciparum methionine aminopeptidase 1b possess antimalarial activity. Proc Natl Acad Sci USA. 2006;103(39):14548-14553.
32. Hadaschik BA, Black PC, Sea JC, et al. A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging. BJU Int. 2007;100(6):1377-1384.
33. Hu X, Addlagatta A, Lu J, et al. Elucidation of the function of type 1 human methionine aminopeptidase during cell cycle progression. Proc Natl Acad Sci USA. 2006;103(48):18148-18153.
34. Griffth EC, Su Z, Niwayama S, et al. Molecular recognition of angiogen-esis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2. Proc Natl Acad Sci USA. 1998;95(26):15183-15188.
35. Hu XV, Chen X, Han KC, et al. Kinetic and mutational studies of the number of interacting divalent cations required by bacterial and human methionine aminopeptidases. Biochemistry. 2007;46(44):12833-12843.
36. Brunet A, Sweeney LB, Sturgill JF, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 2004; 303(5666):2011-2015.
37. Ota H, Tokunaga E, Chang K, et al. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene. 2006;25(2):176-185.
38. Roy S, Packman K, Jeffrey R, et al. Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ. 2005;12(5):482-491.
39. Solomon JM, Pasupuleti R, Xu L, et al. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol. 2006;26(1):28-38.
40. Mariadason JM, Corner GA, Augenlicht LH. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res. 2000;60(16): 4561-4572.
41. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22(1):27-55.
42. Shim JS, Kim JH, Cho HY, et al. Irreversible inhibition of CD13/amino-peptidase N by the antiangiogenic agent curcumin. Chem. Biol. 2003;10(8):695-704.
43. Towbin H, Bair KW, DeCaprio JA, et al. Proteomics-based target identi-fcation: bengamides as a new class of methionine aminopeptidase inhibitors. J Biol Chem. 2003;278(52):52964-52971.
44. Sherr CJ, DePinho RA. Cellular senescence: mitotic clock or culture shock? Cell. 2000;102(4):407-410.
45. Toussaint O, Dumont P, Dierick JF, et al. Stress-induced premature senescence. Essence of life, evolution, stress, and aging. Ann N Y Acad Sci. 2000;908(1):85-98.
46. Cole PA. Chemical probes for histone-modifying enzymes. Nat Chem Biol. 2008;4(10):590-597.
47. Liao Q, Wang J, Webster Y, et al. GPU accelerated support vector machines for mining high-throughput screening data. J Chem Inf Model. 2009;49(12):2718-2725.
48. North BJ, Marshall BL, Borra MT, et al. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell. 2003;11(2): 437-444.
49. Vaquero A, Scher MB, Lee DH, et al. SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. Genes Dev. 2006;20(10): 1256-1261.
50. Heltweg B, Gatbonton T, Schuler AD, et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 2006;66(8):4368-4377.
51. Lain S, Hollick JJ, Campbell J, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008;13(5): 454-463.
52. Potente M, Ghaeni L, Baldessari D, et al. SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev. 2007;21(20): 2644-2658.
53. Albelda SM, Muller WA, Buck CA, et al. Molecular and cellular properties of PECAM-1 (endoCAM/CD31): a novel vascular cell-cell adhesion molecule. J Cell Biol. 1991;114(5):1059-1068.
54. Mrhar A, Kopitar Z, Kozjek F, et al. Clinical pharmacokinetics of nitroxo-line. Int J Clin Pharmacol Biopharm. 1979;17(12):476-481.
55. Jaeger TM, Weidner N, Chew K, et al. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol. 1995; 154(1):69-71.
56. Pearson M, Carbone R, Sebastiani C, et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 2000: 406(6792): 207-210.
57. Langley E, Pearson M, Faretta M, et al. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 2002; 21(10):2383-2396.
58. Murugasu-Oei B, Dick T. In vitro activity of the chelating agents nitroxo-line and oxine against Mycobacterium bovis BCG. Int J Antimicrob Agents. 2001;18(6):579-582.